Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2009)
28 slides from Starpharma's shareholder meeting presentation, Nov 12, 2009
Slide 1: AGM - Chairman's and CEO's presentations
AGM - Chairman’s and CEO’s presentations Melbourne; 12 November 2009: Attached is the Chairman’s address together with the CEO’s For personal use only presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), to be held at 4.00pm today. About Starpharma Starph
Slide 2: Chairman's Address
Chairman’s Address Annual General Meeting of Starpharma Holdings Limited, 12 November 2009 For personal use only Welcome to the Starpharma AGM for the fiscal year 2008–2009. This is my seventh AGM as Chairman of the Starpharma Board, and I am very pleased to be able to once again address you – our C
Slide 3: Chairman's Address (continued)
As part of our broader strategy, we have also pursued partnerships with a number of other international companies this year. Such partnerships allow us to develop our products in an efficient and cost effective way, and provide access to international networks and expertise. Of particular note is ou
Slide 4: CEO Presentation
For personal use only Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Annual General Meeting CEO Presentation 12 November 2009 Dr Jackie Fairley CEO
Slide 5: Forward-looking statements
For personal use only This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targe
Slide 6: Overview
For personal use only Overview Attractive commercial partnerships in place: Starpharma Holdings Limited (11/11/09) – VivaGel® coated condom – simpler regulatory path than drugs ASX Code SPL – Royalty revenues expected to commence in CY11 Level 1 ADR (OTCQX) SPHRY Lead product VivaGel® in clinica
Slide 7: The Year in Review
For personal use only The Year in Review Commercial Development – Full Licence Agreement with Durex® for VivaGel® - coated condom – Signing collaborative agreement with Eli Lilly’s animal health division, Elanco – Execution of Starpharma’s first agrochemical deal with a multi-billion dollar US Co.
Slide 8: Financial Summary
For personal use only Financial Summary Increased Revenues and Prudent Expense Management 2009 2008 $M $M % Royalty, customer & licence revenue 2.0 1.4 43% Grant, interest and other income 7.8 8.5 (8%) Total revenue and income 9.8 9.9 (1%) Net loss after tax (4.1) (7.5) 45% Net cash outflow before n
Slide 9: Share Price Performance – Year
For personal use only Share Price Performance – 1 Year SPL7013 shows Dendrimer Capital raised Completes Interim expanded HPV delivery via $7.1m Financial US patent SPL signs activity institutional capital VivaGel Results – grant reduces agrochemicals placement Elanco raising anti-HIV Material extend
Slide 10: Share Price Performance
For personal use only Share Price Performance ▲ 133% over the last 12 months SPL Outperformed the ASX200, ASX 300 Healthcare & ASX Small Ordinaries indexes 600.0% 540% 500.0% 400.0% 300.0% 246% 225% 200.0% 133% 100.0% 62% 77% 62% 47% 42% 31% 24% 17% 15% 16% 12% 20% 11% 0.0% (6%) (15%) (32%) (22%) (3
Slide 11: Starpharma's Commercial Partnerships and Partnering Strategy
For personal use only Starpharma’s Commercial Partnerships and Partnering Strategy VivaGel® Co-development deal for Condom Coating Dendrimers for Drug Delivery ELANCO Eli Lilly (Elanco), Stiefel (now GSK); Drug delivery research collaborations Stratus CS® Cardiac marker diagnostic licensed to Siemen
Slide 12: Pharmaceutical and Life Sciences Product Pipeline
For personal use only Pharmaceutical and Life Sciences Product Pipeline Lead Products In Clinical Testing: – VivaGel® – condom coating (accelerated program) – VivaGel® “stand-alone” gel – HSV-2 prevention (genital herpes) – HIV prevention – Planning for new trial program: Bacterial Vaginosis Par
Slide 13: VivaGel - for the Prevention of Sexually Transmitted Infections
For personal use only VivaGel® - for the Prevention of Sexually Transmitted Infections (STIs) Two Products in Development VivaGel®-Coated Condom VivaGel® Early opportunity Significance to SPL Main opportunity Anti-viral Condom coating Presentation Applicator + anti-viral gel >>A$100m (est.) Commerci
Slide 14: VivaGel Condom Coating License Agreement with Durex
For personal use only VivaGel® Condom Coating License Agreement with Durex® Estimated total receipts - in excess of A$100m Starpharma to receive: – royalties on SSL sales – milestones – development assistance Value to Starpharma: – Estimated receipts in excess of A$100m SSL CEO Garry Watts: – Ne
Slide 15: VivaGel-Coated Condom Starpharma Income Scenarios
For personal use only VivaGel®-Coated Condom Starpharma Income Scenarios 35 Starpharma annual income 30 25 20 USD(M) 15 Vi vaG 10 el ® 5 0 low med high Fraction of SSL’s range coated with VivaGel® • Early opportunity Key Assumptions: •Global Branded Condom Market est: • Anti-viral Condom Coating US$
Slide 16: Commercial Opportunity for Microbicides
For personal use only Commercial Opportunity for Microbicides Estimated Market* for Microbicides in Developed Countries Industry surveys confirm strong consumer demand 7000 6000 Percentage of female US college students who would 5000 30 - 40% Market Size (US$M) buy a microbicide (without 4000 contra
Slide 17: VivaGel Development Status Update
For personal use only VivaGel® Development Status Update Population In vitro In vivo In vivo Market Phase 1 Phase 2a Based efficacy efficacy safety entry efficacy Currently in Phase 2 clinical trials for prevention of HIV and Genital Herpes Non-dilutive NIH funding >US$26m; extensive development
Slide 18: VivaGel Clinical Trial: Retention of Antiviral Activity
For personal use only VivaGel® Clinical Trial: Retention of Antiviral Activity Conclusion: Potent and sustained activity after Vaginal Administration Objective: – Assessment of antiviral (HIV, HSV-2) activity of VivaGel® in cervicovaginal fluid samples (CVS) taken immediately then 1,3,12,24 hrs af
Slide 19: VivaGel - Bacterial Vaginosis (BV)
For personal use only VivaGel® - Bacterial Vaginosis (BV) The Market Opportunity The most common vaginal infection worldwide 21 million women infected with BV in US, (as high as 51% in certain demographics); Associated with increased risk of HIV & other STIs, unpleasant discharge and linked to
Slide 20: Bacterial Vaginosis Clinical Development Program
For personal use only Bacterial Vaginosis Clinical Development Program Phase 2 Phase 3 • Single, dose ranging • Two pivotal efficacy study studies • N = ~108 • N = ~200 per trial • Test for clinical cure • Test for clinical cure after 7 days, and after 7 days, and • Prevention of • Prevention of rec
Slide 21: Breadth of Dendrimer Opportunity
For personal use only Breadth of Dendrimer Opportunity Human Agricultural Key: Partnership/Funding Drugs Chemicals announced Drug Water Program or partner Delivery Purification discussions in progress Animal Health in vitro Cosmetics diagnostics Laboratory Inks Reagents 18
Slide 22: Strategy for Maximising Commercial Returns from Starpharma's Dendrimers
For personal use only Strategy for Maximising Commercial Returns from Starpharma’s Dendrimers • Conduct proof of concept & enable STARPHARMA partner evaluation • Prove once, partner repeatedly • BD goal - Sector-Leading partners • Development funding PARTNER • Product expertise / market focus • Exis
Slide 23: Application of Dendrimers to Agrochemicals
For personal use only Application of Dendrimers to Agrochemicals Concept: Dendrimer to enhance the performance of existing pesticides •• Extension Extensionof ofdrug drugdelivery deliverytechnology technology •• One Oneagreement agreementannounced announcedto todate date •• AAnumber numberofofdiscus
Slide 24: Application of Dendrimers to Drug Delivery
For personal use only Application of Dendrimers to Drug Delivery Concept: Dendrimer to improve delivery and pharmacokinetic properties of drugs Dermal Research Collaboration : Stiefel Laboratories Inc, a GSK company Payload Drug ELANCO Deal signed with Eli Lilly’s Animal Health Division, Elanco + in
Slide 25: Application of Dendrimers to Drug Delivery: Improved Drug Solubility
For personal use only Application of Dendrimers to Drug Delivery Improved Drug Solubility Utilizing a dendrimer construct the aqueous solubility of the drug Paclitaxel was increased >9,000X. Paclitaxel 30 mg Dendrimer-Paclitaxel 6 mgs in 2 mL of water construct: equivalent to 6 mgs of Paclitaxel in
Slide 26: Application of Dendrimers to Drug Delivery: Reduced Toxicity
For personal use only Application of Dendrimers to Drug Delivery Reduced Toxicity Efficacy of dendrimer-doxorubicin construct was maintained whilst reducing cardiotoxicity Drug alone: Severe Cardiac Toxicity Control Drug with Dendrimer: Protected 23
Slide 27: Value Drivers for Starpharma
For personal use only Value Drivers for Starpharma Advance VivaGel®-Coated Condom to market Complete co-development with SSL plc Regulatory filings and approvals for VivaGel® -coated condoms Commencement of royalty revenue – currently estimated for CY11 Advance VivaGel® through clinical develo
Slide 28: Starpharma Holdings Limited
For personal use only Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Dr Jackie Fairley CEO +613 85322704 Further information: www.starpharma.com info@starpharma.com 25
Starpharma Holdings — Shareholder Meeting (November 2009) on 6ix